U.S. Senate Introduces Bill to Reauthorize Key Stem Cell Transplant Program for Five Years
Event summary
- Bipartisan Senate bill S. 4109 introduced to reauthorize the C.W. Bill Young Cell Transplantation Program for five years.
- Program connects 18,500 annual patients with life-threatening blood diseases to 42 million potential donors and cord blood units.
- NMDP reports 33% increase in patients helped over last five fiscal years (FY2020-FY2025).
- Companion bill H.R. 5160 introduced in September 2025.
The big picture
The reauthorization of the C.W. Bill Young Cell Transplantation Program underscores the critical role of public-private partnerships in advancing stem cell therapies. With 99% of adult patients with common blood cancers now having a suitable donor match, the program's continued funding ensures access to life-saving treatments while driving innovation through data-driven research.
What we're watching
- Legislative Momentum
- Whether the bipartisan support can ensure swift passage of S. 4109 before current authorization expires.
- Program Expansion
- The pace at which NMDP can expand its donor registry and cord blood inventory to meet growing patient demand.
- Research Impact
- How publicly available transplant outcomes data will accelerate innovation in cell therapy treatments.